博士，青年研究员，博士生导师
地址：东安路 131号，治道楼402室，上海 200032
电话：021-54237812（办公室）
邮箱：luo_min@fudan.edu.cn
课题组致力于利用多种生物技术从事肿瘤免疫治疗方面的研究。在肿瘤的免疫治疗领域，我们已开发一种新型纳米疫苗, 能够在体内诱导强烈的特异性T细胞杀伤反应，明显抑制多种肿瘤的发展，例如黑色素瘤、结肠癌等，并与免疫治疗抗体在针对肿瘤的治疗上具有明显的协同作用；相关PCT专利在OncoNano公司（美国）转化，2021年获得5千万美元B轮融资。
目前实验室主要研究方向：
1）开发富集肿瘤抗原的癌症纳米疫苗，并探索可临床转化的更优的联合治疗方案；
2）利用细胞及动物水平技术分析Ｔ细胞和肿瘤免疫微环境的分子机制，开发全新的药物靶点；
3）筛选新的肿瘤免疫相关药物包括小分子、抗体和疫苗，获得针对癌症的更为有效的免疫治疗方案。
代表论文
1.Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, Li X, Shen G, Peng J, Zheng P, Gu Y, Chen J, Lin M, Deng C, Gao H*, Lu Z*, Zhao Y*, Luo M*. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023 Sep, https://doi.org/10.1038/s41586-023-06511-9. (*: corresponding)
2.Ding H, Li Y, Fang M, Chen J, Liu L, Lu Z*, Hou J*, and Luo M*. Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease. Journal of Allergy and Clinical Immunology. 2023 April, https://doi.org/10.1016/j.jaci.2023.04. 003. (*: corresponding)
3.Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Sumer BD, Lea L, Lu Z*, Gao J*, Luo M*. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. Journal For Immunotherapy of Cancer, 2022 May, http://dx.doi.org /10.1136/jitc-2021-003960.(*: corresponding)
4.Gu Y, Cao J, Zhang X, Gao H, Wang Y, Wang J, Jiang X, Zhang J, Shen G, Yang J, Zheng X, Xu J, Lan F, Qu D, Zhao Y, Xu G, Xie Y*, Luo M*, Lu Z* . Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Res, 2022 Jan;32(1):24-37. (*: corresponding)
5.Yang J, Shen G, Cao J, Zhang J, Gu Y, Zhang X, Jiang X, Luo M*, Lu Z*. Efficient expansion of mouse hematopoietic stem cells ex vivo by membrane anchored Angptl2. Biochem Biophys Res Commun. 2022, 617, 42-47. (*: corresponding)
6.Li S, Luo M, Wang Z, Fu YX, Baran S, Yu H , Gao J. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nature Biomedical Engineering. 2021 May; 5(5):455-466.
7.Yin WM, Li YW, Gu YQ, Luo M*. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacol Sin. 2020 Jul;41(7):902-910. (*: corresponding)
8.Miller J, Luo M, ChenZJ, Gao J, Zhao T. ONM-500 – a novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy. Journal For Immunotherapy of Cancer, 2020 April; 8(A7-A8).
9.Luo M, Liu ZD, Fu Yang-Xin, Gao Jinming. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy, Journal of Controlled Release, 2019, 300：154-160.
10.Luo M., Wang H., Wang Z., Cai H., Lu Z., Huang G., Chen X., Porembka M., Frankel A, Zhijian J. Chen, Gao J. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnoloty. 12(7):648-654, 2017.
11.Luo M, Layla Z. Samandi, Zhaohui Wang, Zhijian J. Chen and Jinming Gao, Synthetic nanovaccines for T cell immunotherapy, Journal of Control Release. 263:200-210, 2017, (Invited review)
12.Wang Z.*, Luo M.*, Mao C., Wei Q., Zhao T., Li Y., Huang G., and Gao J. A Redox Activatable Fluorescent Sensor for the High-Throughput Quantification of Cytosolic Delivery of Macromolecules. Angew. Chem. 2017. 129:1339-1343.
13.Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, Kang X, Luo M, Zou Y, Huang LJ, Amatruda JF, Slone T, Winick N, Scherer PE, Zhang CC. Fasting selectively blocks acute lymphoblastic leukemia development via leptin receptor upregulation. Nature Medicine. 2017. 23(1): 79-90.
14.Zhao T., Huang G., Li Y., Yang S., Ramezani S., Lin Z., Wang Y., Ma X., Zeng Z., Luo M., Boer E., Xie X., Thibodeaux J., Brekken RA, Sun X., Sumer BD, Gao J. A transistor-like pH nanoprobe for tumor detection and image-guided surgery. Nature Biomed. Eng. 2016, DOI: 10.1038/s41551-016-0006.
